Zdrowie i gospodarka · 24.02.2014
Draft Guidance for Industry on New Chemical Entity Exclusivity Determinations for Certain Fixed-Combination Drug Products; Availability
The Food and Drug Administration (FDA) is announcing the availability of a draft guidance for industry entitled "New Chemical Entity Exclusivity Determinations for Certain Fixed-Combination Drug Products." This draft guidance sets forth a change in the Agency's interpretation of the 5-year new chemical entity (NCE) exclusivity statutory and regulatory provisions as they apply to certain fixed-combination drug products (fixed combinations). If the guidance is finalized, a drug product will be eligible for 5-year NCE exclusivity if it contains a drug substance that meets the definition of "new chemical entity," regardless of whether that drug substance is approved alone or in certain fixed-combinations.